Background: Insomnia remains one of the most common sleep disorders encountered in the
geriatric clinic population, frequently characterized by the subjective complaint of difficulty …

Introduction: The purpose of this guideline is to establish clinical practice recommendations
for the pharmacologic treatment of chronic insomnia in adults, when such treatment is …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on the management of chronic …

Although the GABAergic benzodiazepines (BZDs) and Z-drugs (zolpidem, zopiclone, and
zaleplon) are FDA-approved for insomnia disorders with a strong evidence base, they have …

Purpose Insomnia is problematic for older adults. After behavioral modifications fail to show
adequate response, pharmacologic options are used. The pharmacokinetics of agents used …

Insomnia poses significant challenges to public health. It is a common condition associated
with marked impairment in function and quality of life, psychiatric and physical morbidity, and …

Background: Pharmacologic interventions are often prescribed for insomnia disorder.
Purpose: To assess the benefits, harms, and comparative effectiveness of pharmacologic …

Melatonin, an endogenous signal of darkness, is an important component of the body's
internal time-keeping system. As such it regulates major physiological processes including …

Chronic insomnia affects 57% of the elderly in the United States, with impairment of quality
of life, function, and health. Chronic insomnia burdens society with billions of dollars in direct …

Sleep‐related disorders are most prevalent in the older adult population. A high prevalence
of medical and psychosocial comorbidities and the frequent use of multiple medications …